6wmh
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Next generation monomeric IgG4 Fc== | ==Next generation monomeric IgG4 Fc== | ||
| - | <StructureSection load='6wmh' size='340' side='right'caption='[[6wmh]]' scene=''> | + | <StructureSection load='6wmh' size='340' side='right'caption='[[6wmh]], [[Resolution|resolution]] 2.30Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6WMH OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6WMH FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6wmh]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6WMH OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6WMH FirstGlance]. <br> |
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6wmh FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6wmh OCA], [https://pdbe.org/6wmh PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6wmh RCSB], [https://www.ebi.ac.uk/pdbsum/6wmh PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6wmh ProSAT]</span></td></tr> | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6wmh FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6wmh OCA], [https://pdbe.org/6wmh PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6wmh RCSB], [https://www.ebi.ac.uk/pdbsum/6wmh PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6wmh ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | In a biologic therapeutic landscape that requires versatility in targeting specificity, valency and half-life modulation, the monomeric Fc fusion platform holds exciting potential for the creation of a class of monovalent protein therapeutics that includes fusion proteins and bispecific targeting molecules. Here we report a structure-guided approach to engineer monomeric Fc molecules to adapt multiple versions of half-life extension modifications. Co-crystal structures of these monomeric Fc variants with Fc neonatal receptor (FcRn) shed light into the binding interactions that could serve as a guide for engineering the half-life of antibody Fc fragments. These engineered monomeric Fc molecules also enabled the generation of a novel monovalent bispecific molecular design, which translated the FcRn binding enhancement to improvement of in vivo serum half-life. | ||
| + | |||
| + | In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance.,Shan L, Dyk NV, Haskins N, Cook KM, Rosenthal KL, Mazor R, Dragulin-Otto S, Jiang Y, Wu H, Dall'Acqua WF, Borrok MJ, Damschroder MM, Oganesyan V Commun Biol. 2021 Sep 8;4(1):1048. doi: 10.1038/s42003-021-02565-5. PMID:34497355<ref>PMID:34497355</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6wmh" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: | + | [[Category: Acqua, W F.Dall]] |
| - | [[Category: Oganesyan | + | [[Category: Dyk, N van]] |
| - | [[Category: Shan L]] | + | [[Category: Oganesyan, V Y]] |
| - | [[Category: | + | [[Category: Shan, L]] |
| + | [[Category: Antibody constant region]] | ||
| + | [[Category: Fragment crystallizable]] | ||
| + | [[Category: Immune system]] | ||
| + | [[Category: Mutated]] | ||
Revision as of 06:56, 22 September 2021
Next generation monomeric IgG4 Fc
| |||||||||||
